Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while ...

Company Performance - Acurx Pharmaceuticals, Inc. (ACXP) has returned 0.8% year-to-date, outperforming the Medical sector, which has returned an average of -4.7% [4] - The Zacks Consensus Estimate for ACXP's full-year earnings has increased by 60.5% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [4] Industry Ranking - Acurx Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, which has 502 stocks and is currently ranked 88 in the Zacks Industry Rank. This industry has lost an average of 4.8% year-to-date, showing that ACXP is performing better than its peers [6] - The Medical group, which includes Acurx Pharmaceuticals, is ranked 6 within the Zacks Sector Rank, indicating a relatively strong position among 16 sector groups [2] Comparison with Peers - BioCryst Pharmaceuticals (BCRX) has also outperformed the Medical sector with a year-to-date return of 32.6% and has a Zacks Rank of 2 (Buy) [5] - The consensus EPS estimate for BioCryst Pharmaceuticals has increased by 339.6% over the past three months, highlighting significant positive analyst sentiment [5]

Personalis (PSNL) shares rallied 7.3% in the last trading session to close at $6.45. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 21.4% gain over the past four weeks.The sudden uptrend in the stock price can be attributed to the positive investor mindset regarding the continued growth in revenues from the sale of Personalis’ pharma tests and services, signifying increasing adoption of its technology.This p ...

Siga Technologies Inc. (SIGA) ended the recent trading session at $6.36, demonstrating a -1.24% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 1.13%. Meanwhile, the Dow experienced a drop of 1.79%, and the technology-dominated Nasdaq saw a decrease of 1.3%. Shares of the company have appreciated by 8.78% over the course of the past month, outperforming the Medical sector's gain of 3.07%, and the S&P 500's gain of 3.55%.The upcoming earnings releas ...

Company Overview - United Therapeutics (UTHR) shares increased by 3.5% to close at $286.14, following a period of decline where the stock lost 7.7% over the past four weeks [1] - The rise in share price is linked to a recovery after a decline due to positive results from a pulmonary arterial hypertension (PAH) study conducted by Insmed, which evaluated a prodrug formulation of UTHR's treprostinil [2] Financial Performance - United Therapeutics is expected to report quarterly earnings of $6.87 per share, reflecting a year-over-year increase of 17.4% [3] - Revenue projections for the upcoming quarter stand at $796.42 million, which is an 11.4% increase compared to the same quarter last year [3] Earnings Estimates and Market Sentiment - The consensus EPS estimate for United Therapeutics has been revised 0.7% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] - The company currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook in the market [4] Industry Context - United Therapeutics operates within the Zacks Medical - Drugs industry, where BioCryst Pharmaceuticals (BCRX) is another player, having closed 2% lower at $10.40 [4] - BioCryst's consensus EPS estimate remains unchanged at $0.02, representing a significant year-over-year change of 133.3% [5]

Company Overview - Astellas Pharma Inc. (ALPMY) is a notable stock in the Medical sector, which consists of 998 individual stocks and ranks 6 in the Zacks Sector Rank [2] - The company currently holds a Zacks Rank of 1 (Strong Buy), indicating strong potential for outperforming the market in the near term [3] Performance Analysis - Astellas Pharma's full-year earnings consensus estimate has increased by 15.3% over the past quarter, reflecting improved analyst sentiment and earnings outlook [4] - Year-to-date, Astellas Pharma has gained approximately 1%, while the average loss in the Medical group is about 2.4%, showcasing its better performance relative to the sector [4] Industry Context - Astellas Pharma belongs to the Medical - Drugs industry, which includes 164 companies and currently ranks 71 in the Zacks Industry Rank [6] - The Medical - Drugs industry has seen an average gain of 3% year-to-date, indicating that Astellas Pharma is slightly underperforming its industry peers [6] Comparative Analysis - Another stock, AtriCure (ATRC), has outperformed the sector with an 8.1% gain year-to-date and has a Zacks Rank of 2 (Buy) [5] - AtriCure is part of the Medical - Products industry, which has 83 stocks and ranks 140, with an average gain of 5.7% since the beginning of the year [7]

Have you been paying attention to shares of Catalyst Pharmaceutical (CPRX) ? Shares have been on the move with the stock up 8.4% over the past month. The stock hit a new 52-week high of $26.58 in the previous session. Catalyst Pharmaceutical has gained 23.8% since the start of the year compared to the -3.5% move for the Zacks Medical sector and the 4% return for the Zacks Medical - Drugs industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn' ...

Core Insights - Defence Therapeutics Inc. has received a Notice of Allowance from the USPTO for its U.S. patent application covering next-generation antibody-drug conjugate (ADC) technology, which includes broad composition-of-matter claims for therapeutically active ADCs [1][2] - The allowed patent application (no. 18/351,291) will potentially grant the company market exclusivity for its proprietary second-generation Accum®-based ADCs until 2043 [2][4] - The company has an established patent portfolio for its Accum® technology, with granted patents in the U.S., Japan, Australia, and Israel, and pending applications in Canada and Europe [3][4] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation ADC products using its proprietary Accum® technology, which enhances the precision delivery of ADCs to target cells [5] - The Accum® technology aims to increase the efficacy and potency of cancer treatments [5]

Petco Health & Wellness (WOOF) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this pet store chain would post earnings of $0.02 per share when it actually produced break-even earnings, delivering a surprise of -100%.Over the last four quarters, the co ...

Company Overview - Esperion Therapeutics (ESPR) shares have increased by approximately 28.6% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the stock's performance and potential catalysts [1] Earnings Estimates - Estimates for Esperion Therapeutics have trended downward, with the consensus estimate decreasing by 25.93% over the past month [2] - The overall direction of estimate revisions indicates a downward shift in expectations for the company [4] VGM Scores - Esperion Therapeutics has a Growth Score of B, a Momentum Score of F, and a Value Score of C, placing it in the middle 20% for the value investment strategy [3] - The aggregate VGM Score for the stock is D, which is relevant for investors not focused on a single strategy [3] Industry Performance - Esperion Therapeutics is part of the Zacks Medical - Drugs industry, which includes Ionis Pharmaceuticals (IONS) [5] - Ionis Pharmaceuticals has seen a 6.2% gain over the past month, with reported revenues of $132 million, reflecting a year-over-year increase of 10.9% [5] - Ionis Pharmaceuticals is expected to report a loss of $0.14 per share for the current quarter, showing a year-over-year improvement of 68.9% [6]